This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Cohen SJ , Dobelbower Jr R , Lipsitz S , Catalano PJ , Sischy B , Smith TJ , Haller DG
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
International Journal of Radiation Oncology Biology Physics. 2005 ;62(5) :1345-1350
AbstractPurpose: The median survival time of patients with locally advanced adenocarcinoma of the pancreas is 8-10 months. Radiation therapy has been used to improve local control and palliate symptoms. This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population. Patients and Methods: One hundred fourteen patients were randomized to receive 59.4 Gy external beam radiotherapy in 1.8 Gy fractions alone or in combination with 5-FU (1,000 mg/m2/day for 4 days by continuous infusion Days 2-5 and 28-31) and MMC (10 mg/m2 on Day 2). Results: One hundred four patients were evaluable for efficacy. Hematologic and nonhematologic toxicities were more common in the combination arm. The response rates were 6% in the radiation therapy arm and 9% in the combination arm. There were no differences in median disease-free survival time (DFS) or overall survival time (OS) between the combination and radiation therapy alone arms: 5.1 vs. 5.0 months, respectively, for DFS (p = 0.19) and 8.4 vs. 7.1 months, respectively, for OS (p = 0.16). Conclusion: The addition of 5-FU and MMC to radiotherapy increased toxicity without improving DFS or OS in patients with locally advanced pancreatic cancer. Alternative drugs for radiosensitization may improve outcome. © 2005 Elsevier Inc.
Notes03603016 (ISSN) Cited By: 2; Export Date: 25 May 2006; Source: Scopus CODEN: IOBPD; DOI: 10.1016/j.ijrobp.2004.12.074 Language of Original Document: English Correspondence Address: Cohen, S.J.; Department of Medical Oncology; Fox Chase Cancer Center; 333 Cottman Avenue Philadelphia, PA 19111-2497, United States; email: S_Cohen@fccc.edu Chemicals/CAS: fluorouracil, 51-21-8; mitomycin C, 50-07-7, 74349-48-7, Antineoplastic Combined Chemotherapy Protocols; Fluorouracil, 51-21-8; Mitomycin, 50-07-7 References: Jemal, A., Tiwari, R.C., Murray, T., Cancer statistics, 2004 (2004) CA Cancer J Clin, 54, pp. 8-29; Burris, H.A., Moore, M.J., Andersen, J., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial (1997) J Clin Oncol, 15, p. 2403; Cohen, S.J., Pinover, W.H., Watson, J.C., Pancreatic cancer (2000) Curr Treat Options Oncol, 1, p. 375; Moertel, C.G., Reitemeier, R.J., Hahn, R.G., Mitomycin-C therapy in advanced gastrointestinal cancer (1968) JAMA, 204, pp. 1045-1048; Buroker, T., Kim, P.N., Groppe, C., 5-FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: A Southwest Oncology Group study (1979) Cancer, 44, pp. 1215-1221; Byfield, J.E., Barone, R., Mendelsohn, J., Infusional 5-FU and X-ray therapy for nonresectable esophageal cancer (1980) Cancer, 45, pp. 703-708; Sischy, B., Remington, J.H., Sobel, S.H., Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation (1980) Surg Gynecol Obstet, 151, pp. 369-371; Haslam, J.B., Cavanaugh, P.G., Stroup, S.L., Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas (1973) Cancer, 32, pp. 1341-1345; Childs, D.S., Moertel, C.G., Holbrook, M., Treatment of malignant neoplasms of the gastrointestinal tract with a combination of 5-fluorouracil and radiation. a randomized double-blind study (1965) Radiology, 84, pp. 843-848; Nigro, N.D., Seydel, H.G., Considine, B., Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal (1983) Cancer, 51, pp. 1826-1829; Franklin, R., Steiger, Z., Vaishampayan, G., Combined modality therapy for esophageal squamous cell carcinoma (1983) Cancer, 51, pp. 1062-1071; Miller, A.B., Hogestraeten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment (1981) Cancer, 47, pp. 207-214; Oken, M.M., Creech, R.H., Tormey, D.C., Toxicity and response criteria of the Eastern Cooperative Oncology Group (1982) Am J Clin Oncol, 5, pp. 649-655; Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations (1958) J Am Stat Assoc, 53, pp. 547-581; Moertel, C.G., Frytak, S., Hahn, Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil (1981) Cancer, 48, pp. 1705-1710, The Gastrointestinal Tumor Study Group R.G.; Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone (1988) J Natl Cancer Inst, 80, pp. 751-755, Gastrointestinal Tumor Study Group; Klaassen, D.J., MacIntyre, J.M., Catton, G.E., Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study (1985) J Clin Oncol, 3, pp. 373-378; Neoptolemos, J.P., Stocken, D.D., Friess, H., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer (2004) N Engl J Med, 350, pp. 1200-1210; Berlin, J.D., Catalano, P., Thomas, J.P., Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297 (2002) J Clin Oncol, 20, pp. 3270-3275; Lawrence, T.S., Chang, E.Y., Hahn, T.M., Radiosensitization of pancreatic cancer cells by 2?,2?- difluoro-2?-deoxycytidine (1996) Int J Radiat Oncol Biol Phys, 34, pp. 867-872; McGinn, C.J., Zalupski, M.M., Shureiqi, I., Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer (2001) J Clin Oncol, 19, pp. 4202-4208.